Table 3.

Secondary analyses of deep vein thrombosis / pulmonary embolism and idiopathic / secondary venous thromboembolism outcomes and their annualized incidence during an average of 7 years of intervention.

Outcome	Calcium and Vitamin D (n=18,176)		Placebo (n=18,106)		Hazard Ratio (95%CI) 1	P value
	No. of cases	Annualized Rate (per 100 p-y)	No. of cases	Annualized Rate (per 100 p-y)
Deep vein thrombosis 2	246	0.19	256	0.20	0.97 (0.82-1.16)	0.76
Pulmonary embolism 2	135	0.11	149	0.11	0.92 (0.73-1.16)	0.48
Idiopathic venous thromboembolism	40	0.03	65	0.05	0.62 (0.42-0.92)	0.02
Secondary venous thromboembolism 3	274	0.21	279	0.22	0.98 (0.83-1.16)	0.85

¹Values are from Cox proportional hazard models stratified on age, history of VTE and randomization arms in the HT and DM trial

²Some participants had both a deep vein thrombosis and a pulmonary embolism, simultaneously or at different times. As a result, the addition of the number of events in the analyses for deep vein thrombosis and pulmonary embolism is greater than the number of events for the analysis of venous thrombosis.

³Defined as secondary if procedure/related, within 3 months of a fracture or an inpatient hospitalization, with a history of cancer (excluding non-melanoma skin cancer) or with current use of oral HT.

Abbreviations: CI = confidence interval ; p-y = person-years ;